Brain Health
FDA Approves Four Neurological Drugs Targeting Alzheimer's, Glioma, and Rare Disease
A roundup of recent FDA brain-health approvals including lecanemab's full Alzheimer's approval and a new glioma drug.
Drug Approval
May 5, 2026 0
Results for "GlycanAge Biomarker"
20 articles
Cancer Research
FDA Approves Oral AML Therapy for Elderly Patients Unfit for Intensive Chemo
Inqovi gains approval for newly diagnosed AML in patients 75+ or with comorbidities, offering a gentler oral treatment route.
Drug Approval
May 22, 2026 0
Brain Health
Four Neurology Drug Approvals Reshaping Brain Disease Treatment
From Alzheimer's to Parkinson's, a wave of novel FDA approvals is expanding treatment options for serious neurological conditions.
Drug Approval
May 8, 2026 0
Metabolic Health
Orforglipron Oral GLP-1 Pill Approved as Obesity Pipeline Heats Up
The FDA reportedly approved Eli Lilly's orforglipron, a daily oral GLP-1 receptor agonist for obesity, marking a potential shift from injectable weight-loss drugs.
Drug Approval
Apr 21, 2026 0
Brain Health
FDA Approves First Drug to Treat Neurologic Complications of Hunter Syndrome
Avlayah (tividenofusp alfa-eknm) becomes the first therapy approved to address brain damage in Hunter syndrome, a rare pediatric disorder.
Drug Approval
Apr 28, 2026 0
Metabolic Health
FDA Approves First Oral GLP-1 Weight Loss Pill Orforglipron
Foundayo (orforglipron) becomes the first oral GLP-1 receptor agonist approved for obesity, offering a pill alternative to injectable Wegovy.
Drug Approval
May 9, 2026 0
Metabolic Health
FDA Approves Foundayo for Weight Loss in Record 50 Days
New GLP-1 drug Foundayo gets fastest FDA approval since 2002, targeting obesity and metabolic health through appetite control.
Drug Approval
Apr 6, 2026 0
Brain Health
FDA Approves First Drug for Hunter Syndrome Brain Complications in Children
Avlayah becomes the first treatment targeting neurologic symptoms of rare genetic disorder affecting 500 Americans.
Drug Approval
Apr 15, 2026 0
Brain Health
Spinraza Gets Higher-Dose Approval to Boost Brain Fluid Exposure in SMA
FDA approves an updated Spinraza regimen for spinal muscular atrophy, targeting improved CSF drug levels for better neurological outcomes.
Drug Approval
Apr 26, 2026 0
Cancer Research
FDA Approves Zenocutuzumab-zbco for Advanced Cholangiocarcinoma
The FDA approved zenocutuzumab-zbco for adults with advanced, unresectable, or metastatic cholangiocarcinoma, a rare and aggressive bile duct cancer with limited treatment options.
Drug Approval
May 13, 2026 0
Cancer Research
Nivolumab Gets FDA Nod for Classical Hodgkin Lymphoma in 2025 Drug Approval Wave
MSK-led research drove 10 FDA cancer drug approvals in 2025, including nivolumab combined with chemotherapy for classical Hodgkin lymphoma.
Drug Approval
May 26, 2026 0
Cancer Research
MSK Research Drives 11 FDA Cancer Drug Approvals in 2025
Memorial Sloan Kettering-led trials produced 11 new FDA-approved cancer therapies in a single year, spanning multiple tumor types.
Drug Approval
May 19, 2026 0
Cancer Research
FDA Grants Expanded Approval to Zongertinib for HER2-Mutant Lung Cancer
The FDA expanded accelerated approval for zongertinib in HER2-mutant NSCLC, marking a targeted therapy milestone for a hard-to-treat mutation.
Drug Approval
May 6, 2026 0
Brain Health
FDA Approves First Treatments for Rare Neurological Conditions
Two breakthrough approvals target Hunter syndrome brain complications and cerebral folate deficiency for the first time.
Drug Approval
Apr 7, 2026 0
Cancer Research
FDA Approves Two New HER2-Targeted Lung Cancer Drugs in 2025
Sevabertinib and zongertinib win FDA approval for HER2-mutant NSCLC, expanding targeted therapy options for previously treated patients.
Drug Approval
May 24, 2026 0
Heart Health
FDA Approves Aficamten for Obstructive Hypertrophic Cardiomyopathy
Myqorzo (aficamten) wins FDA approval for symptomatic obstructive HCM, offering a novel cardiac myosin inhibitor option for patients.
Drug Approval
Jun 14, 2026 0
Cancer Research
FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant Lung Cancer
Zongertinib (Hernexeos) wins FDA accelerated approval for HER2-driven non-small cell lung cancer, offering a targeted oral option.
Drug Approval
Apr 21, 2026 0
Cancer Research
FDA Approves Zongertinib for HER2-Mutated Lung Cancer in February 2026
New targeted therapy offers hope for patients with specific genetic mutations in non-small cell lung cancer.
Drug Approval
Apr 15, 2026 0
Metabolic Health
FDA Fast-Tracks New Weight Loss Drug Foundayo Under Priority Program
Orforglipron approved 294 days ahead of schedule for obesity treatment, marking first drug under new priority voucher system.
Drug Approval
Apr 16, 2026 0
Metabolic Health
FDA Approves Two New Weight Loss Drugs in Record Two-Week Span
Foundayo and Zepbound receive rapid FDA approval for chronic weight management in adults with obesity or weight-related conditions.
Drug Approval
Apr 5, 2026 0
Page 1 of 2Next